Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Cancer Survival Analysis01:21

Cancer Survival Analysis

445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncology Organization and Oncologist Networks Under Medicare Advantage Plans.

JAMA network open·2026
Same author

Interfacial enhancement and stiffness-toughness balance in MDI-compatibilized PBAT/sc-PLA blends.

International journal of biological macromolecules·2026
Same author

Distinct H3K27 Methylation States Drive Cellular Responses to the Histone Demethylase Inhibitor GSK-J4 in Ovarian Cancer Cells.

Molecular cancer therapeutics·2026
Same author

Guideline-concordant care and outcomes for pediatric malaria cases: descriptive evidence from pharmacy-based fever management in Kenya.

Malaria journal·2026
Same author

Feasibility and signals of efficacy of the Type 1 Diabetes Education and Support (T1DES) intervention to improve diabetes distress and glycemic levels among Black young adults with type 1 diabetes compared to standard diabetes education: study protocol for a randomized pilot trial.

Pilot and feasibility studies·2026
Same author

Medicare Plan Switching and Hospice Care Among Decedents With Advanced Cancer.

JAMA network open·2026

Related Experiment Video

Updated: Sep 8, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

661

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients With Metastatic

Jingxuan Zhao1,2,3, Ilana Graetz2,3, David Howard2,3

  • 1Department of Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

JAMA Network Open
|July 7, 2025
PubMed
Summary

The introduction of immune checkpoint inhibitors (ICIs) widened the survival gap for uninsured cancer patients compared to those with private insurance. This highlights the need for policies to improve insurance access and treatment affordability.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Related Experiment Videos

Last Updated: Sep 8, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

661
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Area of Science:

  • Oncology
  • Health Services Research
  • Health Economics

Background:

  • Immune checkpoint inhibitors (ICIs) have improved cancer survival.
  • High ICI costs pose affordability challenges for uninsured individuals.
  • Understanding survival disparities by insurance status is crucial.

Purpose of the Study:

  • To assess the impact of ICI introduction on survival disparities in advanced-stage cancer patients.
  • To compare survival changes across different health insurance coverage groups (private, Medicaid, uninsured).

Main Methods:

  • Serial cross-sectional study using the National Cancer Database (2002-2019).
  • Included patients aged 18-64 with stage IV melanoma, NSCLC, or RCC.
  • Propensity score weighting difference-in-differences (DID) analysis examined 2-year overall survival pre- and post-ICI approval.

Main Results:

  • Survival disparities widened between uninsured and privately insured patients for melanoma (6.1 pp) and NSCLC (1.3 pp).
  • No significant survival difference changes were observed between Medicaid and privately insured patients.
  • Overall survival rates increased for both uninsured and privately insured patients post-ICI approval.

Conclusions:

  • ICI introduction exacerbated survival inequalities based on insurance status.
  • Policies are needed to expand health insurance coverage and reduce treatment costs.
  • Addressing financial barriers is essential for equitable cancer care.